Man-Chiu Poon

List of Publications by Year
in descending order

81	1,799	257357 24	289141 40
papers	citations	h-index	g-index

82	82	82	1507
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Activated Platelets Harbor SARS-CoV-2 during Severe COVID-19. Thrombosis and Haemostasis, 2022, 122, 308-309.	1.8	2
2	Demographics, clinical profile and treatment landscape of patients with haemophilia B in China. Haemophilia, 2022, 28, .	1.0	3
3	Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian realâ€world, multicenter, retrospective study. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12661.	1.0	4
4	Proteomics and Metabolomics Profiling of Platelets and Plasma Mediators of Thrombo-Inflammation in Gestational Hypertension and Preeclampsia. Cells, 2022, 11, 1256.	1.8	14
5	Nephrotic syndrome in two haemophilia B children with inhibitor under lowâ€dose immune tolerance induction combined with rituximabâ€based immunosuppressant protocol. Haemophilia, 2022, 28, .	1.0	1
6	Eradication of FIX inhibitor in haemophilia B children using lowâ€dose immune tolerance induction with rituximabâ€based immunosuppressive agent(s) in China. Haemophilia, 2022, , .	1.0	3
7	A lowâ€dose immune tolerance induction (ITI) protocol incorporating immunosuppressive agents in haemophilia A children with highâ€titre factor VIII inhibitor and poorâ€ITI prognostic risk. Haemophilia, 2021, 27, e469-e472.	1.0	2
8	The Use of Recombinant Activated Factor VII in Patients with Glanzmann's Thrombasthenia. Thrombosis and Haemostasis, 2021, 121, 332-340.	1.8	20
9	Patients with haemophilia A with inhibitors in China: a national realâ€world analysis and followâ€up. British Journal of Haematology, 2021, 192, 900-908.	1.2	7
10	Longâ€term joint outcomes of regular lowâ€dose prophylaxis in Chinese children with severe haemophilia A. Haemophilia, 2021, 27, 237-244.	1.0	5
11	The Function of extravascular coagulation factor IX in haemostasis. Haemophilia, 2021, 27, 332-339.	1.0	22
12	Factor product utilization and health outcomes in patients with haemophilia A and B on extended halfâ€life concentrates: A Canadian observational study of realâ€world outcomes. Haemophilia, 2021, 27, 751-759.	1.0	9
13	Lowâ€dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12562.	1.0	6
14	Current status of haemophilia inhibitor management in mainland China: a haemophilia treatment centres survey on treatment preferences and realâ€world clinical practices. British Journal of Haematology, 2021, 194, 750-758.	1.2	2
15	Surgery in mild haemophilia A patients with a history of inhibitor antibodies against factor VIII: Individualized management. Haemophilia, 2021, 27, e768-e771.	1.0	1
16	The impact of extended halfâ€life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12601.	1.0	5
17	Iron dosing frequency. Canadian Family Physician, 2021, 67, 436.	0.1	0
18	A Pharmacist-Managed Hydroxyurea Prescribing Protocol Improves Uptake and Optimization Among Patients with Sickle Cell Disease within the Southern Alberta Rare Blood and Bleeding Disorders (SARBBD) Comprehensive Care Program. Blood, 2021, 138, 1896-1896.	0.6	0

#	Article	IF	Citations
19	Emicizumab Outcomes in Hemophilia A Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry. Blood, 2021, 138, 347-347.	0.6	0
20	Bleeding assessment in haemophilia carriersâ€"High rates of bleeding after surgical abortion and intrauterine device placement: A multicentre study in China. Haemophilia, 2020, 26, 122-128.	1.0	8
21	Severe haemophilia A children on lowâ€dose tertiary prophylaxis showed less joint deterioration and better maintenance of functional independence than children on onâ€demand treatment: A 6â€year followâ€up study. Haemophilia, 2020, 26, 779-785.	1.0	5
22	Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome. Blood, 2020, 136, 1956-1967.	0.6	34
23	Haemophilia care in China: Achievements in the past decade. Haemophilia, 2020, 26, 759-767.	1.0	20
24	Management of haemophilia patients in the COVIDâ€19 pandemic: Experience in Wuhan and Tianjin, two differently affected cities in China. Haemophilia, 2020, 26, 1031-1037.	1.0	4
25	A previously treated severe haemophilia A patient developed high-titre inhibitor after vaccinations. International Journal of Immunopathology and Pharmacology, 2020, 34, 205873842093461.	1.0	3
26	Platelet Membrane Procoagulation in Preeclampsia. Blood, 2020, 136, 7-7.	0.6	2
27	Lowâ€dose immune tolerance induction for children with hemophilia A with poorâ€risk highâ€titer inhibitors: A pilot study in China. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 741-748.	1.0	11
28	The International Prospective Glanzmann Thrombasthenia Registry: Pediatric Treatment and Outcomes. TH Open, 2019, 03, e286-e294.	0.7	12
29	Healthcare professionals in the â€˜tainted bloodâ€™ era in Canada: Their forgotten emotions. Haemophilia, 2019, 25, 651-655.	1.0	4
30	Effect of an electronic treatment plan on acute management of hereditary angioedema. Annals of Allergy, Asthma and Immunology, 2019, 123, 98-100.	0.5	2
31	Factor VIIa. , 2019, , 1121-1135.		0
32	The International/Canadian Hereditary Angioedema Guideline. Allergy, Asthma and Clinical Immunology, 2019, 15, 72.	0.9	112
33	Samuel Armstrong Lane's first successful treatment of haemophilia with blood transfusion in 1840: Could this also be the first successful bypassing therapy?. Haemophilia, 2019, 25, e45-e47.	1.0	1
34	Building a network for hemophilia care in China: 15 years of achievement for the Hemophilia Treatment Center Collaborative Network of China. Blood Advances, 2019, 3, 34-37.	2.5	16
35	Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A. Chinese Medical Journal, 2018, 131, 1780-1785.	0.9	10
36	Ischemic Strokes in a Man with Congenital Afibrinogenemia. Canadian Journal of Neurological Sciences, 2018, 45, 590-592.	0.3	5

#	Article	IF	Citations
37	Glanzmann Thrombasthenia. , 2018, , 327-355.		1
38	Desmopressin in nonâ€severe haemophilia A: Testâ€response and clinical outcomes in a single Canadian centre review. Haemophilia, 2018, 24, 720-725.	1.0	6
39	Inherited platelet functional disorders: General principles and practical aspects of management. Transfusion and Apheresis Science, 2018, 57, 494-501.	0.5	31
40	Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort. Lancet Haematology,the, 2018, 5, e252-e260.	2.2	31
41	Alloimmunization in Congenital Deficiencies of Platelet Surface Glycoproteins: Focus on Glanzmann's Thrombasthenia and Bernardâ€“Soulier's Syndrome. Seminars in Thrombosis and Hemostasis, 2018, 44, 604-614.	1.5	18
42	Observational Study of Real-World Factor Utilization and Health Outcomes in Patients with Hemophilia in Canada. Blood, 2018, 132, 4813-4813.	0.6	1
43	Independent adjudicator assessments of platelet refractoriness and rFVIIa efficacy in bleeding episodes and surgeries from the multinational Glanzmann's thrombasthenia registry. American Journal of Hematology, 2017, 92, 646-652.	2.0	10
44	Glanzmannâ€™s thrombasthenia: strategies for identification and management. Expert Opinion on Orphan Drugs, 2017, 5, 641-653.	0.5	6
45	Thrombosis in Inherited Fibrinogen Disorders. Transfusion Medicine and Hemotherapy, 2017, 44, 70-76.	0.7	56
46	Low-dose tertiary prophylactic therapy reduces total number of bleeds and improves the ability to perform activities of daily living in adults with severe haemophilia A. Blood Coagulation and Fibrinolysis, 2016, 27, 136-140.	0.5	25
47	Safety and efficacy of tranexamic acid in bleeding paediatric trauma patients: a systematic review protocol. BMJ Open, 2016, 6, e012947.	0.8	13
48	Characterization of aberrant splicing of von Willebrand factor in von Willebrand disease: an underrecognized mechanism. Blood, 2016, 128, 584-593.	0.6	17
49	Individualized prophylaxis for optimizing hemophilia care: can we apply this to both developed and developing nations?. Thrombosis Journal, 2016, 14, 32.	0.9	28
50	New Insights Into the Treatment of Glanzmann Thrombasthenia. Transfusion Medicine Reviews, 2016, 30, 92-99.	0.9	95
51	Premature changes in trabecular and cortical microarchitecture result in decreased bone strength in hemophilia. Blood, 2015, 125, 2160-2163.	0.6	23
52	The international prospective Glanzmann Thrombasthenia Registry: treatment and outcomes in surgical intervention. Haematologica, 2015, 100, 1038-44.	1.7	53
53	Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions. BMC Hematology, 2015, 15, 4.	2.6	23
54	The international prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes in non-surgical bleeding episodes in Glanzmann thrombasthenia patients. Haematologica, 2015, 100, 1031-7.	1.7	43

#	Article	IF	Citations
55	Acquired von Willebrand syndrome: von Willebrand factor propeptide to von Willebrand factor antigen ratio predicts remission status. Blood, 2014, 124, e1-e3.	0.6	11
56	Hemophilia management in transfusion medicine. Transfusion and Apheresis Science, 2012, 46, 299-307.	0.5	5
57	The International Prospective Glanzmann's Thrombasthenia Registry (GTR) Special Issues in Children. Blood, 2012, 120, 3341-3341.	0.6	1
58	2B or not to be â€“ The 45-year saga of the Montreal Platelet Syndrome. Thrombosis and Haemostasis, 2010, 104, 903-910.	1.8	10
59	Glanzmannâ€™s thrombasthenia (defective platelet integrin Î±IIb-Î²3): proposals for management between evidence and open issues. Thrombosis and Haemostasis, 2009, 102, 1157-1164.	1.8	57
60	The Montreal platelet syndrome kindred has type 2B von Willebrand disease with the VWF V1316M mutation. Blood, 2009, 113, 3348-3351.	0.6	58
61	Long term platelet responses to Helicobacter pylori eradication in Canadian patients with immune thrombocytopenic purpura. International Journal of Hematology, 2008, 88, 212-218.	0.7	42
62	Use of Factor VIII/Von Willebrand Factor Complex for Inducing Immune Tolerance in Hemophilia a Patients Who Have Failed with Recombinant Fviii: Recent Canadian Experience. Blood, 2008, 112, 4520-4520.	0.6	0
63	Factor VIIa. , 2007, , 1251-1261.		0
64	The Evidence for the Use of Recombinant Human Activated Factor VII in the Treatment of Bleeding Patients With Quantitative and Qualitative Platelet Disorders. Transfusion Medicine Reviews, 2007, 21, 223-236.	0.9	62
65	Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia. Vascular Health and Risk Management, 2007, 3, 655-64.	1.0	31
66	Glanzmannâ€™s Thrombasthenia Treatment: A Prospective Observational Registry on the Use of Recombinant Human Activated Factor VII and Other Hemostatic Agents. Seminars in Hematology, 2006, 43, S33-S36.	1.8	37
67	Management of thrombocytopenic bleeding: is there a role for recombinant coagulation factor VIIa?. Psychophysiology, 2003, 2, 139-47.	1.1	20
68	Recombinant Factor IX Recovery and Inhibitor Safety: A Canadian Post-licensure Surveillance Study. Thrombosis and Haemostasis, 2002, 87, 431-435.	1.8	106
69	Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study. Thrombosis and Haemostasis, 2002, 87, 431-5.	1.8	15
70	Use of recombinant factor VIIa (NovoSevenÂ®) in patients with Glanzmann thrombasthenia. Seminars in Hematology, 2001, 38, 21-25.	1.8	57
71	Use of recombinant factor VIIa in hereditary bleeding disorders. Current Opinion in Hematology, 2001, 8, 312-318.	1.2	58
72	Therapeutic choices for patients with hemophilia and high-titer inhibitors. American Journal of Hematology, 2001, 67, 240-246.	2.0	58

#	Article	IF	Citations
73	Recombinant Factor VIIa Is Effective for Bleeding and Surgery in Patients With Glanzmann Thrombasthenia. Blood, 1999, 94, 3951-3953.	0.6	195
74	A Hemi-nested, Allele Specific, Whole Blood PCR Assay for the Detection of the Factor V Leiden Mutation. Thrombosis and Haemostasis, 1997, 77, 1154-1155.	1.8	7
75	Characterization of an acquired IgG inhibitor of coagulation factor XIII in a patient with systemic lupus erythematosus. British Journal of Haematology, 1996, 93, 700-703.	1.2	24
76	Factor XIIIA calgary: a candidate missense mutation (Leu667Pro) in the beta barrel 2 domain of the factor XIIIAsubunit. British Journal of Haematology, 1995, 91, 452-457.	1.2	29
77	Contractile actions of thrombin receptorâ€derived polypeptides in human umbilical and placental vasculature: evidence for distinct receptor systems. British Journal of Pharmacology, 1995, 115, 569-578.	2.7	27
78	Lymphocyte Membrane Modifications Induced by HIV Infection.. Tohoku Journal of Experimental Medicine, 1994, 173, 115-131.	0.5	10
79	Severe combined immune deficiency presenting with cyclic hematopoiesis. Journal of Clinical Immunology, 1991, 11, 369-377.	2.0	1
80	Treatment of an aggressive non-Hodgkin's lymphoma during pregnancy with MACOP-B chemotherapy. Medical and Pediatric Oncology, 1990, 18, 143-145.	1.0	28
81	G6PD Viangchan: a new glucose 6-phosphate dehydrogenase variant from Laos. Human Genetics, 1988, 78, 98-99.	1.8	13